MAVERICK CAPITAL LTD: BOSTON SCIENTIFIC CORP (BSX): Quarterly 13F Position History
As of Q1 2026, MAVERICK CAPITAL LTD reported 4,195,089 shares of BOSTON SCIENTIFIC CORP (BSX), worth $263.2M and representing 3.1% of its 13F equity book. Quarter-over-quarter share count change: + 1,250,835 (+42.5%) . The position first appeared in Q1 2018 and has been disclosed across 33 13F-HR filings in Pactolio's tracked window.
- 4,195,089Shares Held (Latest Filing)
- $263.2MReported Market Value (Latest Filing)
- 3.1%Portfolio Weight (% of 13F Equity Book)
- +1,250,835Quarter-over-Quarter Share Change
- -$17.5MQuarter-over-Quarter Value Change
- 4,195,089Peak Reported Shares (Historical)
Quarterly 13F-HR Disclosure History Source: SEC 13F-HR filings, 33 quarter s
| Quarter | Shares | QoQ Share Change | Share Change (%) | Market Value | Weight | Implied Price |
|---|---|---|---|---|---|---|
| Q1 2026 | 4,195,089 | +1,250,835 | +42.5% | $263.2M | 3.1% | $62.8 |
| Q4 2025 | 2,944,254 | +2,944,254 | — | $280.7M | 3.0% | $95.3 |
| Q3 2025 | 0 | 0 | — | $0 | 0.0% | — |
| Q2 2025 | 0 | 0 | — | $0 | 0.0% | — |
| Q1 2025 | 0 | 0 | — | $0 | 0.0% | — |
| Q4 2024 | 0 | 0 | — | $0 | 0.0% | — |
| Q3 2024 | 0 | 0 | — | $0 | 0.0% | — |
| Q2 2024 | 0 | 5,748 | -100.0% | $0 | 0.0% | — |
| Q1 2024 | 5,748 | 3,083 | -34.9% | $393.7K | 0.0% | $68.5 |
| Q4 2023 | 8,831 | +8,831 | — | $510.5K | 0.0% | $57.8 |
| Q3 2023 | 0 | 0 | — | $0 | 0.0% | — |
| Q2 2023 | 0 | 0 | — | $0 | 0.0% | — |
| Q1 2023 | 0 | 0 | — | $0 | 0.0% | — |
| Q4 2022 | 0 | 0 | — | $0 | 0.0% | — |
| Q3 2022 | 0 | 0 | — | $0 | 0.0% | — |
| Q2 2022 | 0 | 0 | — | $0 | 0.0% | — |
| Q1 2022 | 0 | 0 | — | $0 | 0.0% | — |
| Q4 2021 | 0 | 62,528 | -100.0% | $0 | 0.0% | — |
| Q3 2021 | 62,528 | 32,668 | -34.3% | $2.7M | 0.0% | $43.4 |
| Q2 2021 | 95,196 | +62,070 | +187.4% | $4.1M | 0.0% | $42.8 |
| Q1 2021 | 33,126 | 36,915 | -52.7% | $1.3M | 0.0% | $38.6 |
| Q4 2020 | 70,041 | +5,745 | +8.9% | $2.5M | 0.0% | $36.0 |
| Q3 2020 | 64,296 | +64,296 | — | $2.5M | 0.0% | $38.2 |
| Q2 2020 | 0 | 0 | — | $0 | 0.0% | — |
| Q1 2020 | 0 | 0 | — | $0 | 0.0% | — |
| Q4 2019 | 0 | 0 | — | $0 | 0.0% | — |
| Q3 2019 | 0 | 0 | — | $0 | 0.0% | — |
| Q2 2019 | 0 | 0 | — | $0 | 0.0% | — |
| Q1 2019 | 0 | 77,730 | -100.0% | $0 | 0.0% | — |
| Q4 2018 | 77,730 | +77,730 | — | $2.7M | 0.0% | $35.3 |
| Q3 2018 | 0 | 0 | — | $0 | 0.0% | — |
| Q2 2018 | 0 | 71,740 | -100.0% | $0 | 0.0% | — |
| Q1 2018 | 71,740 | — | — | $2.0M | 0.0% | $27.3 |
Methodology & FAQ
How This Position History Is Sourced
Each row is one SEC Form 13F-HR filing disclosing this position. Share count, market value, and reported quarter are taken verbatim from the filing; portfolio weight is recomputed against the same filing's total reported equity book. Implied price-per-share is market value divided by shares — a quarter-end mark, not the manager's cost basis. See the full methodology document for the normalization rules.
When did MAVERICK CAPITAL LTD first disclose a BSX position in 13F-HR filings?
MAVERICK CAPITAL LTD first reported BOSTON SCIENTIFIC CORP (BSX) on its 13F-HR filing for the period ending 2018-03-31 (Q1 2018). The position has appeared on 33 reported quarters within Pactolio's tracked window.
What was MAVERICK CAPITAL LTD's most recent quarter-over-quarter share-count change in BSX?
Between Q4 2025 and Q1 2026, MAVERICK CAPITAL LTD added 1,250,835 shares of BSX (+42.5%), bringing the total reported position to 4,195,089 shares at a market value of $263.2M.
Does the implied price-per-share represent MAVERICK CAPITAL LTD's cost basis in BSX?
No. The implied price-per-share column is the 13F-HR reported market value divided by reported share count on the filing date (end of quarter). It is a quarter-end mark, not a cost basis or transaction price. Use it as a sanity check on the value column, not as an indicator of the manager's entry or exit price.